查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945891

疟疾诊断市场－全球产业规模、份额、趋势、机会及预测（依技术、最终用户、地区及竞争格局划分，2021-2031年）

Malaria Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球疟疾诊断市场预计将从 2025 年的 8.6 亿美元成长到 2031 年的 12.1 亿美元，复合年增长率为 5.86%。

此市场领域涵盖用于识别疟疾原虫的试剂和医疗设备（特别是显微镜、快速诊断测试和分子检测）的生产和供应。推动这一成长的关键因素包括国际社会对疟疾消除倡议的持续财政支持，以及在疟疾高负担地区迫切需要准确的就地检验以辅助治疗决策。全球基金在2024年发布的一份报告预测，“将有3.6亿例疑似疟疾病例接受检测”，这一数字凸显了全球卫生框架对诊断覆盖率的持续关注。

市场概览
预测期 2027-2031
市场规模：2025年 8.6亿美元
市场规模：2031年 12.1亿美元
复合年增长率：2026-2031年 5.86%
成长最快的细分市场 快速诊断测试
最大的市场 亚太地区

阻碍市场发展的主要障碍是寄生虫中pfhrp2和pfhrp3基因缺失的发生率不断上升，导致最常用的基于抗原的快速诊断测试失效。这种生物抗药性迫使人们采用替代的、通常更昂贵的诊断设备，从而使供应链管理更加复杂，并在资源匮乏的环境中加剧国家卫生计画预算的压力。

市场驱动因素

增加国际津贴和财政支持对全球疟疾诊断市场至关重要，尤其考虑到疟疾负担沉重的国家对外部援助的依赖程度。全球基金和美国总统疟疾控制倡议等机构为资源匮乏地区采购快速诊断检测套组和显微镜试剂提供了必要的资金。这些资金保障了供应链，并激励製造商在利润微薄的情况下维持生产水准。根据Devex网站2024年3月发表的题为「国会宣布支出协议」的报导，美国政府在其2024财年预算中核准了7.95亿美元的双边疟疾控制项目专项预算。然而，人们仍然担忧长期的资金永续性。健康政策观察组织在2024年4月世界疟疾日发布的报告指出，实现全球疟疾控制目标的年度资金缺口已扩大至约37亿美元。

地方性疟疾流行区域疾病负担日益加重，气候变迁导致感染区域扩大，直接推动了对诊断检测的需求。气候模式的改变正迫使蚊子向传统上无疟疾的高海拔和高纬度地区迁徙，使原本不常出现疟疾的人面临感染风险，因此必须实施快速筛检措施。这种地理和人口结构的变化迫使各国卫生系统扩大就地检验盒的储备，以应对疑似病例的激增并避免疫情爆发。根据路透社2023年12月发表的题为《全球疟疾病例上升》的报导，预计2022年全球疟疾病例将达到2.49亿例，主要原因是巴基斯坦和衣索比亚等国的疫情爆发。这迫使生产商将分销网络扩展到这些新的感染热点地区。

市场挑战

pfhrp2 和 pfhrp3 基因缺失的出现对全球疟疾诊断市场构成了严重的生物学障碍。这些基因突变会导致标准且经济高效的快速诊断测试出现假阴性结果，从根本上削弱了初始检测程序的可靠性。因此，医疗系统被迫转向其他诊断技术，而这些技术通常高成本，物流也更复杂。这种对替代方案的迫切需求在市场上造成了巨大的摩擦，需要对供应链进行根本性的改革以支持非 HRP2 检测，从而导致采购和分销效率下降。

这项挑战阻碍了市场成长，因为它将原本用于扩张的关键资金转移。各国卫生倡议被迫将有限的预算重新分配给检验和采购更昂贵的替代设备，而不是将诊断服务扩展到服务不足的地区。这种衝击的规模巨大且影响广泛，世界卫生组织 (WHO) 2024 年的报告指出，「在 40 多个国家已发现 pfhrp2 和 pfhrp3 基因缺失」。这种广泛的影响迫使市场进入高成本的产品配方调整期，导致高负担地区的普及速度放缓。

市场趋势

将人工智慧 (AI) 和机器学习技术整合到数位显微镜中，透过自动检测和定量寄生虫，正在改变诊断标准，有助于缓解疟疾流行地区熟练显微镜操作人员严重短缺的问题。这些先进的光学系统采用深度学习演算法，能够以一致的准确度检查血液涂片，显着降低高强度环境下人工阅片固有的人为误差率。这项技术进步对于准确检测非恶性疟疾原虫和低寄生虫血症病例尤其重要，因为这些病例往往会被传统的目视检查漏诊。正如2024年11月发表在《韩国生物医学评论》上的报导「Noul 在美国会议上推出具有卓越准确度的人工智慧疟疾诊断工具」所报道，在尼日利亚进行的临床试验表明，人工智慧驱动的 miLab MAL 平台灵敏度高达94.4%，显着优于传统的现场人工显微镜检查。

为了克服基于抗原的快速检测灵敏度不足以及集中式PCR检查室的后勤障碍，医疗系统正迅速转向照护现场诊断平台。透过将核酸扩增技术整合到携带式电池供电设备中，製造商使地区级卫生中心能够以基因检测的准确性确诊疑似病例，这对于识别抗药性标记和监测根除工作至关重要。分子检测的这种去中心化透过建立基于仪器安装和耗材销售的新收入来源，增强了市场。根据2024年5月《BioSpectrum India》一篇报导「MolBio Diagnostics采用新时代技术，于2024年推出颠覆性产品」的文章，MolBio Diagnostics预计在2024-2025财年的收入将达到1200亿印度卢比，这主要得益于其Truenat平台在其上的广泛部署资源。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球疟疾诊断市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按技术分类（分子诊断测试、快速诊断测试、其他）
    • 依最终使用者（医院/诊所、诊断中心、居家医疗、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美疟疾诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲疟疾诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区疟疾诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲疟疾诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲疟疾诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球疟疾诊断市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Access Bio., Inc.
  • Abbott Laboratories
  • Premier Medical Corporation Pvt. Ltd.
  • Sysmex Partec GmbH
  • bioMerieux
  • Beckman Coulter, Inc.
  • Siemens Healthineers
  • Leica Microsystems GmbH
  • Nikon Corporation
  • Olympus Corporation
  • Bio-Rad Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 15000

The Global Malaria Diagnostics Market is projected to expand from USD 0.86 Billion in 2025 to USD 1.21 Billion by 2031, registering a CAGR of 5.86%. This market sector covers the production and provision of reagents and medical devices-specifically microscopy, Rapid Diagnostic Tests, and molecular assays-designed to identify Plasmodium parasites. Key factors fueling this growth include continuous international financial support for malaria eradication initiatives and the urgent requirement for precise point-of-care testing to direct treatment in regions with high disease burdens. As noted by 'The Global Fund' in '2024', '360 million suspected cases of malaria were tested', a figure that emphasizes the ongoing focus on diagnostic reach within global health frameworks.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.86 Billion
Market Size 2031USD 1.21 Billion
CAGR 2026-20315.86%
Fastest Growing SegmentRapid Diagnostic Test
Largest MarketAsia Pacific

A major obstacle hindering market progression is the rising occurrence of pfhrp2 and pfhrp3 gene deletions in parasites, which causes the most commonly utilized antigen-based Rapid Diagnostic Tests to fail. This biological resistance compels the adoption of alternative, frequently costlier diagnostic instruments, thereby complicating supply chain management and straining budget allocations for national health programs in resource-constrained environments.

Market Driver

Rising international grants and funding act as the cornerstone for the Global Malaria Diagnostics Market, especially considering the dependence of high-burden countries on external assistance. Entities like The Global Fund and the U.S. President's Malaria Initiative supply the necessary capital to acquire rapid diagnostic tests and microscopy reagents globally for low-resource areas. This funding secures the supply chain and motivates manufacturers to uphold production levels despite thin profit margins. According to Devex in March 2024, the article 'Congress releases spending deal' noted that the U.S. government authorized US$ 795 million specifically for bilateral malaria programs in the 2024 fiscal budget; however, long-term financial viability is a concern, as a 'World Malaria Day' report by Health Policy Watch in April 2024 indicated the annual funding gap for global malaria targets has grown to roughly US$ 3.7 billion.

The increasing disease load in endemic areas, worsened by the climate-driven widening of transmission zones, is directly fueling the demand for diagnostic testing volumes. Changing weather patterns are causing mosquitoes to migrate to higher elevations and previously malaria-free latitudes, exposing unaccustomed populations to infection and demanding the swift implementation of screening measures. This geographical and demographic shift obliges national health systems to bolster their stocks of point-of-care solutions to handle the spike in suspected cases and avert outbreaks. As reported by Reuters in December 2023 in the 'Global malaria cases rise' article, global malaria cases were estimated at 249 million in 2022, largely due to outbreaks in nations such as Pakistan and Ethiopia, forcing manufacturers to expand distribution networks to these emerging hotspots.

Market Challenge

The growing incidence of pfhrp2 and pfhrp3 gene deletions constitutes a severe biological hurdle for the Global Malaria Diagnostics Market. These genetic mutations lead standard, cost-efficient rapid diagnostic tests to yield false-negative outcomes, fundamentally compromising the reliability of initial testing procedures. Consequently, healthcare systems must shift toward alternative diagnostic techniques that are generally more costly and logistically intricate. This urgent requirement for substitution generates considerable market friction, as supply chains require overhaul to support non-HRP2 tests, resulting in setbacks regarding procurement and distribution efficiency.

This difficulty inhibits market growth by redirecting crucial financial assets away from expansion efforts. National health initiatives are forced to reassign restricted budgets toward validating and acquiring these more expensive alternative instruments instead of broadening diagnostic access for underserved communities. The scale of this disruption is significant and widespread; according to the 'World Health Organization' in '2024', 'pfhrp2 and pfhrp3 gene deletions were reported in over 40 countries'. This broad reach compels the market into an expensive period of product restructuring, thereby retarding the pace of volume adoption in high-burden areas.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into Digital Microscopy is transforming diagnostic standards by automating parasite detection and quantification, helping to resolve the acute scarcity of trained microscopists in endemic zones. These sophisticated optical systems employ deep learning algorithms to examine blood smears with uniform accuracy, drastically lowering human error rates common in manual slide reading within high-volume environments. This technological advancement is especially critical for correctly detecting non-falciparum species and low-parasitemia cases often overlooked by standard visual checks. As reported by Korea Biomedical Review in November 2024, in the article 'Noul showcases AI-powered malaria diagnostic tool with superior accuracy at US meet', a clinical trial in Nigeria showed that the AI-enabled miLab MAL platform reached a sensitivity of 94.4 percent, significantly surpassing traditional manual microscopy in the field.

The shift toward Point-of-Care Molecular Diagnostic Platforms is rapidly gathering momentum as health systems aim to overcome the sensitivity constraints of antigen-based rapid tests and the logistical hurdles of central laboratory PCR. By compacting nucleic acid amplification technology into portable, battery-powered units, manufacturers allow district-level centers to verify suspected cases with genomic precision, which is vital for identifying drug-resistance markers and overseeing elimination efforts. This decentralization of molecular testing reinforces the market by establishing new revenue streams based on instrument placement and consumable cartridge sales. According to BioSpectrum India in May 2024, in the 'MolBio Diagnostics deploys new-age technologies to launch innovative products in 2024' article, Molbio Diagnostics anticipated revenue of Rs 1200 crore for the 2024-25 fiscal year, primarily fueled by the broader rollout of its Truenat molecular platform in resource-constrained markets.

Key Market Players

  • Access Bio., Inc.
  • Abbott Laboratories
  • Premier Medical Corporation Pvt. Ltd.
  • Sysmex Partec GmbH
  • bioMerieux
  • Beckman Coulter, Inc.
  • Siemens Healthineers
  • Leica Microsystems GmbH
  • Nikon Corporation
  • Olympus Corporation
  • Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Malaria Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Diagnostics Market, By Technology

  • Molecular Diagnostic Tests
  • Rapid Diagnostic Test
  • Others

Malaria Diagnostics Market, By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Home care
  • Others

Malaria Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Diagnostics Market.

Available Customizations:

Global Malaria Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Molecular Diagnostic Tests, Rapid Diagnostic Test, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Centers, Home care, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Malaria Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malaria Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Malaria Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Malaria Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By End User

7. Europe Malaria Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malaria Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By End User
    • 7.3.2. France Malaria Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Malaria Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Malaria Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Malaria Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By End User

8. Asia Pacific Malaria Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malaria Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By End User
    • 8.3.2. India Malaria Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Malaria Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Malaria Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Malaria Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By End User

9. Middle East & Africa Malaria Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malaria Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Malaria Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Malaria Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By End User

10. South America Malaria Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Malaria Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Malaria Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malaria Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Access Bio., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories
  • 15.3. Premier Medical Corporation Pvt. Ltd.
  • 15.4. Sysmex Partec GmbH
  • 15.5. bioMerieux
  • 15.6. Beckman Coulter, Inc.
  • 15.7. Siemens Healthineers
  • 15.8. Leica Microsystems GmbH
  • 15.9. Nikon Corporation
  • 15.10. Olympus Corporation
  • 15.11. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer